Cargando…

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING

Detalles Bibliográficos
Autores principales:	Ren, Xiying, Thomas, Alexander, Meng, Yiran, Nerlov, Claus, Valletta, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428312/ http://dx.doi.org/10.1097/01.HS9.0000967424.81121.56

Ejemplares similares

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY
por: Wei, Yujun, et al.
Publicado: (2023)

S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
por: Rutella, Sergio, et al.
Publicado: (2023)

Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGFβ1 as regulators of hematopoietic ageing
por: Valletta, Simona, et al.
Publicado: (2020)

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
por: Gyurkocza, Boglarka, et al.
Publicado: (2023)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter
por: Sendker, Stephanie, et al.
Publicado: (2021)

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment
por: Tabe, Yoko, et al.
Publicado: (2023)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

Nasal Angiomyolipoma (AML) Mimicking Juvenile Nasopharyngeal Angiofibroma
por: Ameen, Saiful-Azhar, et al.
Publicado: (2019)

Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy
por: You, Ruolan, et al.
Publicado: (2021)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

S282: ERYTHROPOIESIS INDUCTION THROUGH BONE MARROW TFR2 DELETION REDUCES BLOOD GLUCOSE LEVELS IN WILD-TYPE AND Β-THALASSEMIC MICE
por: Maria DI Modica, Simona, et al.
Publicado: (2023)

S286: TARGETING CONDITIONING-ELICITED NON-TRANSFERRIN-BOUND IRON BY TMPRSS6 SILENCING IMPROVES BONE MARROW TRANSPLANT OUTCOME
por: Antypiuk, Ada, et al.
Publicado: (2023)

Transmissible ER Stress Reconfigures the AML Bone Marrow Compartment
por: Doron, Ben, et al.
Publicado: (2018)

S188: CAR-T CELLS SHAPE THE IMMUNOLOGICAL POTENTIAL OF THE TUMOR MICROENVIRONMENT
por: Frede, Julia, et al.
Publicado: (2023)

S208: RELEVANCE OF DORMANT CANCER STEM CELLS IN DISEASE PROPAGATION AND THERAPY RESISTANCEIN JAK2V617F-DRIVEN MPN.
por: Ghezzi, Ian, et al.
Publicado: (2023)

S177: JAK INHIBITION AND COMBINATION THERAPY IN THE TREATMENT OF MURINE BONE MARROW FAILURE
por: Feng, Xingmin, et al.
Publicado: (2023)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

S237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA
por: Suehara, Yasuhito, et al.
Publicado: (2023)

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
por: Lehner, Kara M., et al.
Publicado: (2023)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
por: Haubner, Sascha, et al.
Publicado: (2023)

S284: HEPATOCYTE TOLL-LIKE RECEPTORS MEDIATE THE HEPCIDIN INFLAMMATORY RESPONSE TO PATHOGENS AND PATHOGEN-DERIVED LIGANDS
por: Bonitz, Katharina, et al.
Publicado: (2023)

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment
por: Tabe, Yoko, et al.
Publicado: (2013)

G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
por: Osuorji, Ikenna, et al.
Publicado: (2012)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

S174: MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP
por: Pleyer, Lisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3upmp85dov5vh5iiu62sho8p3f